Corticosteroid-free remission (secondary endpoint)

Corticosteroid-free remission (secondary endpoint)

With ZEPOSIA, significantly more patients achieved corticosteroid-free remission (secondary endpoint)* at 52 weeks vs. placebo1

You are advised to read the study design information before these efficacy outcomes

Secondary endpoint: Corticosteroid-free remission (remission with no steroid use for ≥12 weeks) at week 52.1*

Graph showing almost twice as many participants achieved corticosteroid-free remission on ZEPOSIA at 52 weeks vs a placebo in the TRUE NORTH study

Blue icon with arrows pointing outwards, representing a zoom optionPinch & zoom to explore

In the TRUE NORTH study:

  • Nearly twice as many patients
    who received ZEPOSIA achieved corticosteroid-free remission at 52 weeks vs. placebo1

Adapted from Sandborn WJ et al. 2021.

Key secondary efficacy endpoints were assessed in a pre-specified hierarchical testing procedure. The ranked secondary endpoints for the maintenance period (52 weeks) were percentages of patients with a clinical response, endoscopic improvement, maintenance of clinical remission, corticosteroid free remission, mucosal healing, and durable remission.1

*Corticosteroid-free remission was defined as clinical remission at 52 weeks without receipt of glucocorticoids for at least 12 weeks.
CI, confidence interval.

References

  1. Sandborn WJ et al. NEJM 2021; 385(14):1280–1291.

Legal Notice | Privacy Policy

Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Ireland-via HPRA Pharmacovigilance at www.hpra.ie Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK); 1800 749 749 (Ireland).

© 2022 Bristol-Myers Squibb Company. All rights reserved.
Job: 2084-GB-2300276 Date of Preparation: June 2023